Chemomab Therapeutics (CMMB) Net Cash Flow Growth (1y) (2018 - 2023)
Chemomab Therapeutics (CMMB) Net Cash Flow Growth (1y) (2018 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Chemomab Therapeutics | 724.52 Mn | 714.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -94.96% |
| Sep 30, 2023 | -243.12% |
| Jun 30, 2023 | -162.80% |
| Mar 31, 2023 | 645.22% |
| Dec 31, 2022 | 112.32% |
| Sep 30, 2022 | 111.21% |
| Jun 30, 2022 | 69.08% |
| Mar 31, 2022 | -102.86% |
| Dec 31, 2021 | -2,166.93% |
| Sep 30, 2021 | -2,031.48% |
| Jun 30, 2021 | -674.99% |
| Mar 31, 2021 | 3,368.03% |
| Dec 31, 2020 | 82.43% |
| Sep 30, 2020 | 90.46% |
| Jun 30, 2020 | 143.34% |
| Mar 31, 2020 | -105.78% |
| Dec 31, 2019 | -38.46% |
| Sep 30, 2019 | 55.85% |
| Jun 30, 2019 | -127.10% |
| Mar 31, 2019 | 3,252.62% |